MAM01 monoclonal antibody shows early promise against malaria

US researchers have developed a novel monoclonal antibody, MAM01, that has shown dose-dependent full protection against malaria in an early clinical trial. The study was conducted by the University of Maryland School of Medicine’s Center for Vaccine Development and Global Health (CVD).

Single Injection Could Offer Months-Long Protection

• Unlike conventional vaccines that often require multiple doses or boosters, a single injection of MAM01 could provide immediate and long-lasting protection, offering a fundamentally new approach to prevent malaria infection before it starts.
• The trial reported minimal side effects, enhancing the potential for safe widespread use.

Targeting the Malaria Parasite

• MAM01 targets a highly conserved region of the Plasmodium falciparum circumsporozoite protein, preventing the parasite from entering the bloodstream.
• This method blocks infection at an early stage, unlike treatments that act after infection occurs.

Global Malaria Burden

• Malaria is a leading cause of death among children in sub-Saharan Africa, claiming over 600,000 lives annually worldwide.
• Current vaccines and treatments have limited effectiveness, underscoring the need for innovative preventive strategies.

Monoclonal Antibodies Explained

• Monoclonal antibodies (mAbs or Moabs) are lab-made immune proteins derived from a single clone of a B cell.
• They specifically target one antigen, unlike polyclonal antibodies, which target multiple antigens.
• mAbs are already used to treat cancer and other diseases, and now show potential in preventing infectious diseases like malaria.

Significance
The success of MAM01 represents a major breakthrough in malaria prevention, offering a potentially faster, longer-lasting, and more targeted alternative to traditional vaccines.

(Sources: DD News & Cancer.Org)